1	HOGAN LOVELLS US LLPOFFICE OF THE GENERAL COUNSEL				
	SOUTH COAST AIR QUALITY MANAGEMEN		200		
2	J. Tom Boer (State Bar No. 199563)MARY REIC tom.boer@hoganlovells.comSenior Deputy Distric	et Counsel			
3	Maia H. Jorgensen (State Bar No. 344980) maia.jorgensen@hoganlovells.com		l.gov		
4	21865 Copley Drive4 Embarcadero Center, Suite 3500 San FranciscoDiamond Bar, California 941181765-0940				
5	TelephoneEL: (415) 374-2300 909.396.3400 • FAXFacsimile: (415) 374-2499 909.396.2961				
6	Attorneys for PetitionerRespondent				
7	B. BRAUN US PHARMACEUTICAL MANUFACTURING LLCSouth Coast Air Quality Management District				
8					
9	BEFORE THE HEARING BOARD OF THE				
10	SOUTH COAST AIR QUALITY MANAGEMENT DISTRICT				
11					
12	In the Matter of	Case No. 4780	-5		
13	B. BRAUN US PHARMACEUTICAL				
14	MANUFACTURING LLCMEDICAL INC. [Facility ID No. 117290]	[PROPOSED] DECISION	FINDINGS AND		
15	Petitioner,				
16	VS.	South Coast AQMD Rule 1134			
17	SOUTH COAST AIR QUALITY	Hearing Date:	October 24 December 19,		
18	MANAGEMENT DISTRICT,	202 <u>4</u> 3 Time:	9:30 a.m.		
19	Respondent.	Place:	Hearing Board South Coast Air Quality		
20			Management District 21865 Copley Drive		
21]	Diamond Bar, CA 91765		
22	FINDINGS AND DECISION OF THE HEARING BOARD				
23	I HADINGS MAD DECISION OF THE HEARING BOARD				
24	This On December 19, 2023, a Petition for a Regular Variance ("Petition") was heard on				
25	December 19, 2023, pursuant to notice and <u>in</u> accordance with the provisions of the California Health				
26	and Safety Code section 40826 and South Coast AQMD Rule 510. The Petition was subsequently				
27	granted, and a regular variance was issued by the Hearing Board on December 21, 2023. On May 29,				
28	B. BRAUN <u>US PHARMACEUTICAL MANUFACTURING LLCMEDICAL INC.</u> [FID# 117290] – FINDINGS & DECISION [PROPOSED]				

2024, B. Braun Medical Inc. ("BMI") notified the Hearing Board that ownership and operation of its 1 2 pharmaceutical manufacturing facility located at 2525 McGaw Avenue in Irvine, California (the 3 "Irvine Facility"), which is subject to the variance, was transferred to an affiliate entity, B. Braun US Pharmaceutical Manufacturing LLC ("Petitioner" or "Pharma"). Pharma is now responsible for 4 compliance with the variance. On August 30, 2024, Pharma filed a Petition for Extension of a Final 5 Compliance Deadline, in connection with the variance (the "Extension Petition"). On October 24, 6 7 2024, the Hearing Board held a hearing pursuant to California Health and Safety Code section 40826 8 and South Coast AQMD Rule 510, to consider an extension of the variance compliance deadlines, as requested in the Extension Petition. The following members of the Hearing Board were present: 9 10 Micah AliCynthia Verdugo-Peralta, Chair; Robert Pearman, Vice-Chair; Mohan Balagopalan; Jerry P. Abraham, MD; and Cynthia Verdugo-PeraltaMicah Ali. Petitioner B. Braun Medical Inc. 11 ("Petitioner" or "B. Braun"), was represented by J. Tom Boer, Esq., and Maia Jorgensen, Esq., 12 Hogan Lovells US LLP, did not appear. Respondent, Executive Officer of the South Coast Air 13 Quality Management District ("South Coast AQMD" or "Respondent"), was represented by Mary 14 Reichert, Senior Deputy District Counsel, did not appear. The parties have stipulated to the issuance 15 of this Order. The public was given the opportunity to testify. Evidence was received and the matter 16 was submitted. The Hearing Board finds and decides as follows: 17

18 **Nature of Business and Location of Facility**

Petitioner <u>Pharma B. Braun</u> is a medical equipment manufacturing company operating <u>the</u>
<u>Irvine Facility, which is a modernized, 710,000 sq. ft. pharmaceutical manufacturing facility located</u>
at <u>2525 McGaw Avenue</u> in Irvine, California (the "Irvine Facility"), within the jurisdiction of the
South Coast AQMD. The Facility ID Number is 117290.

23 Equipment and Permit to Construct/Operate

The equipment that is the subject of th<u>e variance spetition</u> consists of Turbine No. 1 (Device
D28) operated pursuant to Permit to Operate No. 432956 and Turbine No. 2 (Device D35) operated
pursuant to Permit to Operate No. 542242 (collectively, the "Turbines").

27 28

B. BRAUN <u>US PHARMACEUTICAL MANUFACTURING LLCMEDICAL INC.</u> [FID# 117290] – FINDINGS & DECISION [PROPOSED]

South Coast AQMD Rule 1134 requires an emission standard of 2 ppm NOx @ 15% O2 -2-

1 for all stationary Natural Gas-Fueled Cogeneration Single Cycle Turbines effective January 1, 2024.

2

SUMMARY

Petitioner is will be in violation of District Rule 1134 because Turbines No. 1 and 2 do not			
meet the Rule 1134 2 ppm NOx limitation that took will be in effect onas of January 1, 2024.			
Petitioner must continue to operate Turbines No. 1 and 2 because delivery and installation of the			
replacement technology wasill not be completed in time to meet the January 1, 2024 deadline.			
Despite an initial estimate of completion that would have met the January 1, 2024 deadline,			
Petitioner's contractor has notified them that they wouldill be unable to complete delivery and			
installation of compliant equipment until October 2024. This resulted in a final compliance deadline			
for the variance of October 31, 2024. Since issuance of the regular variance on December 21, 2023,			
BMI and Petitioner have diligently pursued installation of replacement technology that will bring			
the facility into compliance with District rules and allow for the decommissioning of the Turbines.			
Nevertheless, for reasons outside of Petitioner's control, Pharma has been made aware that certain			
required upgrades to the Southern California Edison ("SCE") electrical yard at the Irvine Facility			
will delay operationalization of replacement technology until January 2025.			
FINDINGS OF FACT AND CONCLUSIONS			
Following are the facts and conclusions supporting the findings set forth in Health and Safety			
Code Section 42352 necessary to grant the variance. The Executive Officer did not oppose the			
granting of the regular variance.			
a. The Petitioner for a variance is or will be in violation of Section 41701, or of any rule,			
a. The Petitioner for a variance is or will be in violation of Section 41701, or of any rule, regulation, or order of the South Coast AQMD.			
Petitioner is will be in violation of District Rule 1134 because Turbines No. 1 and 2 do not			
meet the Rule 1134 2 ppm NOx limitation that tookwill be in effect on as of January 1, 2024.			
Petitioner must continue to operate Turbines No. 1 and 2 because delivery and installation of the			
replacement technology wasill not be completed in time to meet the January 1, 2024 deadline.			
b(1). Non-compliance with District Rule(s) is due to conditions beyond the reasonable control of the Petitioner.			
-3- B. BRAUN US PHARMACEUTICAL MANUFACTURING LLCMEDICAL INC. [FID# 117290] – FINDINGS &			
DECISION [PROPOSED]			

1	BMIPetitioner began a process in late 2018 to identify a feasible alternative for power
2	generation at the Irvine Facility as required to meet the Rule 1134 deadline. Petitioner-BMI signed
3	an Energy Services Agreement ("ESA") with Bloom Energy ("Bloom") to replace Turbines No. 1
4	and 2 with two natural gas fuel cell systems (the "Fuel Cells") to comply with the Rule 1134 2 ppm
5	limit. When signing the contract in December 2022, Bloom agreed to a penalties provision in the
6	ESA in the event the Fuel Cells are not operational within 18 months. However, in the second
7	quarter of 2023, it became evident to Petitioner BMI that Bloom would not meet the January 1, 2024
8	deadline. The project delay was driven by a number of converging factors including unexpected
9	complications with the City of Irvine permitting process (due to the City changing its position by
10	requiring a City Master Plan modification process before issuing otherwise required permits for the
11	project), longer than expected procurement lead times for electrical switchgears necessary for the
12	project, and unanticipated challenges with various aspects of the project design including gas supply
13	engineering.
14	Since issuance of the regular variance on December 21, 2023, BMI and Petitioner have
15	diligently pursued installation of replacement technology that will bring the Irvine Facility into
16	compliance with District rules and allow for the decommissioning of the Turbines. Certain aspects
17	of the project, however, rely upon work performed by SCE. Such work is performed based upon the
18	availability of SCE personnel and resources and is outside the direct control of Petitioner. Despite
19	Petitioner's best efforts, in May of 2024, SCE notified Petitioner that certain structural and electrical
20	upgrades must be completed at the SCE yard located adjacent to the Irvine Facility's Switchyard A
21	before SCE will allow tie-in of the Fuel Cells into the electrical grid, which is an essential step to
22	operationalizing the Fuel Cells. Based on estimates provided by SCE, it is contemplated that the
23	necessary upgrades will be completed by the end of December 2024, after which the Fuel Cells can
24	be energized. Bloom estimates a month will be required after energization of the Fuel Cells to
25	complete the project. These unexpected project delays, which were outside Petitioner's control,
26	form the basis of Petitioner's request for an extension of the final variance compliance deadline to
27	

28

1 January 31, 2025.

2

3

b(2). Requiring compliance would result in either (1) an arbitrary or unreasonable taking of property, or (2) the practical closing and elimination of a lawful business.

Petitioner's Irvine Facility produces over 100 medical products including premixed 4 5 intravenous (IV) solutions, generic drugs, antibiotics, and nutrition therapy formulations. The Facility plays a critical role in the health care sector, as it produces approximately 20 percent of the 6 7 IV solutions used in the United States. The Facility operates twenty-four hours a day, seven days a week, relying heavily on consistent energy generated by its two natural gas-fueled Turbines. These 8 turbines are essential for the operation of the Facility. Shutting down of the Turbines without 9 10 alternative power could result in \$2 million per day of lost revenues and significant disruption to the healthcare system. 11

- 12
- 13

c.

The closing or taking would be without a corresponding benefit in reducing air contaminants.

Estimated excess emissions are 9.77 pounds of NOx per day. This is not a significant amount 14 15 of emissions when weighed against the significant impacts of a potential shutdown of the Facility. There are also long-term benefits to the Facility's decision to replace its natural gas-fueled 16 17 Turbines with the Fuel Cells as compared to installing replacement cogeneration turbines. Once 18 installed, NOx emissions for the Fuel Cells will be approximately 0.0017 lbs/MWh, which will result in annual emissions that are significantly below the Rule 1134 limit. Within a year of the 19 20 installation and start-up of the Fuel Cells, emissions saving from the conversion to the Fuel Cells 21 will effectively cancel out the excess NOx emissions expected to be generated by the Turbines 22 during the requested original 10-month variance period. After that one--year period, NOx emissions associated with the Fuel Cells will continue to be orders of magnitude less than the annual NOx 23 24 emissions that would have occurred if PharmaB. Braun had instead installed cogeneration turbines 25 compliant with the newly effective January 1, 2024, NOx emission limitations for cogeneration turbines. The limited, additional excess NOx emissions generated during a three-month extension 26 27 of the variance through January 31, 2025, will not materially change the benefits of the Fuel Cell -5-28 TURING LLCMEDICAL INC. [FID# 117290] – FINDINGS & DECISION [PROPOSED]

project as recognized in the original variance.

2

1

3

d.

The Petitioner for the variance has given consideration to curtailing operations of the source in lieu of obtaining a variance.

Curtailing or terminating operations at the Irvine Facility would have serious medical supply
chain implications, result in breach of customer contracts, and have severe financial repercussions
for <u>PharmaB. Braun</u>. Several of the products Petitioner manufacturers at the Irvine Facility are or
have recently been on the FDA drug shortages list. Curtailing operations would have a negative
impact on millions of patients across California and the United States.

- 9
- 10

24

e. During the period the variance is in effect, the Petitioner will reduce excess emissions to the maximum extent feasible.

The Turbines have a permitted, maximum rated capacity of 6MW. During the variance period, B. BraunPharma has will reduced its reliance on the Turbines to 4.5MW as measured on a weekly average basis. This represents a 25% reduction below the Turbines' maximum rated capacity (and a further 10% reduction below the Petitioner's original estimation of power needed from the Turbines during the variance). This is the maximum reduction PharmaB. Braun can achieve during the variance period without compromising its manufacturing operations and its ability to maintain sufficient catalyst temperature to meet emissions requirements for air contaminants (e.g., carbon

18 monoxide). Petitioner will also continue to operate the Turbines in compliance with all other

19 applicable permit conditions and keep the Turbines in proper working condition.

f. During the period the variance is in effect, the Petitioner will monitor or otherwise quantify emission levels from the source, if requested to do so by the District, and report these emission levels to the District pursuant to a schedule established by the District.

22 Petitioner will continue to operate the CEMS units and report emissions as required under

- 23 RECLAIM and the conditions under this Order.
 - <u>ORDER</u>
- 25 THEREFORE, good cause appearing, the Hearing Board orders as follows:
- A. Petitioner is granted a regular variance from District Rule 1134 for Turbine No. 1
- 27 (D28) operating pursuant to Permit to Operate No. 432956 and Turbine No. 2 (D35) operating
- 28 -6-B. BRAUN <u>US PHARMACEUTICAL MANUFACTURING LLCMEDICAL INC.</u> [FID# 117290] – FINDINGS & DECISION [PROPOSED]

pursuant to Permit to Operate No. 542242, for the period commencing January November 1, 2024
 and continuing through January 31, 2025 October 31, 2024, the final compliance date.

3

Β.

The variance granted herein is subject to the following conditions:

1. Petitioner shall maintain records of NOx emissions in pounds per day, and 4 5 fuel usage records in million cubic feet per day, for each Turbine Device ID D28 and D35 starting 01/01/24. emailed shall 6 These records be Air Ouality Inspector to Paolo 7 Longoni(plongoni@aqmd.gov) on a quarterly basis, no later than close of business (COB) on the 5th day of the month following the end of each quarter. 8

9 2. Petitioner shall calculate NOx excessive emissions, in pounds per day, for
10 each Turbine Device ID D28 and D35 starting 01/01/24 using the difference between the current
11 NOx limit of 9 ppm (as set by Permit to Operate condition no. A99.1) and the future NOX limit of
12 2 ppm (as set by Rule 1134). These records shall be emailed to Air Quality Inspector Paolo Longoni
13 (plongoni@aqmd.gov) on a quarterly basis, no later than COB on the 5th day of the month following
14 the end of each quarter.

3. Petitioner shall not operate the Turbines, in combination, to exceed 4.5MW
of power as measured by the Petitioner on an average weekly basis. Petitioner shall record the
weekly average power generation from the Turbines, which shall be included in Petitioner's
quarterly report to Air Quality Inspector Paolo Longoni.

Petitioner shall maintain the existing Relative Accuracy Test Audits (RATAs)
 schedule for once every six months (or every twelve months if the incentive is met) for each Turbine
 Device ID D28 and D35 as required by Rule 2012.

22 5. Petitioner shall perform a full service per the manufacturer's specifications of
23 Turbines Device ID D28 and D35 at least once every two calendar quarters.

6. Petitioner shall report the progress of this project to South Coast AQMD on a
quarterly basis, which includes the status of all design, demolition, and construction activities related
to the replacement of Turbines Device ID D28 and D35 with two new Fuel Cells. <u>Petitioner shall</u>
include, with each quarterly report, a Gantt chart showing the status of the Fuel Cells project. These
-7-

reports shall be emailed to Air Quality Inspector Paolo Longoni (plongoni@aqmd.gov) and Air
 Quality Engineer Faye Ganser (fganser@aqmd.gov) no later than COB on the 5th day of the month
 following the end of each quarter.

7. Petitioner shall timely submit complete information for the two new Fuel
Cells, consistent with Rule 222, in a format determined by the Executive Officer. Information for
the Fuel Cells submitted pursuant to Rule 222 should be submitted online to
PermitServicesOnline@aqmd.gov and confirmation of the application submittals shall be provided
to Air Quality Engineer Faye Ganser (fganser@aqmd.gov) @aqmd.gov) by email.

9 Petitioner shall comply with the following Increments of Progress: 8. 10 a. November 28, 2024: Outage to prepare SCE onsite yard for upgrades. b. December 24, 2024: SCE yard upgrades complete. 11 c. December 30, 2024: Commencement of Fuel Cells operation. 12 13 d. January 29, 2025: Fuel Cells microgrid transfer complete. Within two business days of the deadline for the completion of each Increment of Progress, 14 15 Petitioner shall submit via email to Air Quality Inspector Paolo Longoni (plongoni@aqmd.gov) an updated Gantt chart for the Fuel Cells project. 16 17 Petitioner shall install and begin initial operation of the two new Fuel Cells <u>8</u>.9. 18 no later than COB JanuaryOctober 4, 20254. 19 9.10. Petitioner shall achieve final compliance no later than COB JanuaryOctober 2031. 20254. Petitioner shall notify by email Air Quality Inspector Paolo Longoni (plongoni@aqmd.gov) of the following events as they occur: 21 The construction start date, the installation completion date, and the date 22 a. each new Fuel Cell becomes operational; and 23 24 b. Achieving final compliance. 25 10.11. Petitioner shall notify the Clerk of the Hearing Board at clerkofboard@aqmd.gov when final compliance is achieved. 26 27 11.12. Petitioner shall pay any excess emissions fees to the Clerk of the Board on a -8-28 CMEDICAL INC. [FID# 117290] – FINDINGS & DECISION [PROPOSED]

1	quarterly basis no later than COB on the 30th day of the month following the end of each quarter or	
2	this variance shall be invalidated pursuant to Rule 303(k). The first payment will be due be due on	
3	April 30, 2024.	
4	FOR THE BOARD:	
5	DATE SIGNED:	
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27	0	
28	-9- B. BRAUN <u>US PHARMACEUTICAL MANUFACTURING LLCMEDICAL INC.</u> [FID# 117290] – FINDINGS & DECISION [PROPOSED]	